Literature DB >> 21538722

Patient preference in choosing biological therapy in Crohn's disease.

S T C Peake, J Landy, M Hussein, C T Tee, M O'Connor, T Tyrrell, A Akbar, A L Hart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21538722     DOI： 10.1002/ibd.21767

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  3 in total

1.  Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

Authors:  Mark T Osterman; Kevin Haynes; Elizabeth Delzell; Jie Zhang; Meenakshi Bewtra; Colleen Brensinger; Lang Chen; Fenlong Xie; Jeffrey R Curtis; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

Review 2.  Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review.

Authors:  Alex Al Khoury; Bhairavi Balram; Talat Bessissow; Waqqas Afif; Lorant Gonczi; Maria Abreu; Peter L Lakatos
Journal:  Dig Dis Sci       Date:  2021-05-21       Impact factor: 3.487

3.  Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.

Authors:  Jae Myung Cha; Dong Il Park; Sang Hyoung Park; Jeong Eun Shin; Wan Soo Kim; Suk Kyun Yang
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.